Persica Taps Biotech Veterans to Advance Chronic Pain Breakthrough

LONDON, UK – March 23, 2026

Persica Pharmaceuticals, a clinical-stage biotechnology company, has signaled a major strategic shift by appointing two seasoned industry leaders to its executive team. The move comes as the company prepares to advance its promising non-opioid treatment for chronic Low Back Pain (cLBP), PP353, into late-stage development following highly encouraging early clinical results.

Dr. Edward Littler, an expert microbiologist renowned for steering biotech firms to lucrative acquisitions, takes the helm as Executive Chairman. He is joined by David Watson, a 35-year life sciences veteran with extensive experience at industry giants like Biogen and Amgen, who will serve as the new Chief Executive Officer. The appointments coincide with the retirement of co-founder Steve Ruston, who has led the company for 13 years and will transition to a Non-Executive Director role on the board. This leadership overhaul positions Persica to capitalize on a pivotal moment in its history, armed with strong clinical data and the executive firepower to navigate the path to market.

A New Era of Leadership for a Pivotal Moment

The appointments of Dr. Littler and Mr. Watson are a clear statement of intent from Persica Pharmaceuticals. The company is transitioning from a research-focused entity to one poised for late-stage clinical trials, regulatory submissions, and potential commercialization—a phase that demands a specific and proven skill set.

Dr. Littler brings a formidable track record of both scientific acumen and corporate success. As the former CEO of ReViral Ltd, he was the architect behind the development of a first-in-class Respiratory Syncytial Virus (RSV) inhibitor, raising over $100 million and ultimately orchestrating the company’s $550 million acquisition by Pfizer in 2022. His deep expertise in drug development is further evidenced by his current roles as Executive Chairman of drug discovery service provider Domainex and Chairman of MetalloBio. His experience turning scientific promise into tangible commercial value will be critical for Persica.

“I'm delighted to be joining Persica at this pivotal moment in the company's development,” Dr. Littler stated. “The Phase 1b data provide compelling proof-of-concept that directly targeting the underlying infection in the disc can deliver meaningful and durable improvements for a significant group of patients with chronic Low Back Pain - and offer an opioid-sparing treatment.”

Complementing Littler’s strategic oversight is David Watson, whose operational and clinical development expertise is extensive. Having held senior leadership positions at Biogen, Amgen, and Immunocore, Watson has a deep understanding of the complexities of advancing drug candidates through the final, most challenging stages of development. His direct role in securing more than $200 million in financing for various ventures also addresses a crucial need for Persica as it prepares for the capital-intensive phases ahead.

“David brings exceptional scientific, clinical and strategic insight that will be instrumental as Persica moves from early clinical validation to late-stage development,” Dr. Littler added.

Beyond Opioids: A Targeted Attack on Chronic Back Pain

At the heart of Persica's strategic pivot is PP353, a potentially transformative therapy for a debilitating condition that affects millions. The drug targets a specific subgroup of patients with chronic Low Back Pain associated with Modic type 1 changes—inflammatory markers visible on MRI scans that are often linked to a low-grade bacterial infection within the vertebral disc. This patient group, estimated at four million across the US, EU, and Japan, often suffers from moderate to severe pain and finds little relief from the current standard of care, which includes physiotherapy and analgesics, frequently escalating to opioids.

The results from the company’s randomised, double-blind, sham-controlled Phase 1b trial, published in The Lancet’s eClinicalMedicine, have provided the first strong clinical evidence for this novel approach. The study demonstrated that a single injection of PP353 significantly reduced pain, improved patients' daily function, and decreased their reliance on painkillers, including opioids. The data was considered significant enough to be selected for an oral presentation at the prestigious American Society of Interventional Pain Physicians (ASIPP) 2026 Annual Meeting.

PP353 is not just another painkiller; it is designed as a disease-modifying treatment. It consists of linezolid, a powerful antibiotic, suspended in a unique thermosensitive vehicle. Delivered via a targeted intradiscal injection, the formulation is liquid at room temperature but becomes a viscous gel at body temperature. This innovative mechanism prevents the drug from leaking out of the damaged disc, ensuring it remains at the site of the suspected infection to eradicate the underlying cause of the inflammation and pain.

“Chronic Low Back Pain affects millions of people worldwide who remain poorly served by existing therapies that primarily manage symptoms without addressing the underlying cause,” said new CEO David Watson. “We now have an opportunity to further investigate the disease-modifying potential of PP353 in later-stage trials and to change the way chronic Low Back Pain is treated.”

The Founder's Handover and Strategic Vision

The leadership transition also marks a new chapter in the story of Persica's founder, Steve Ruston. After 13 years at the helm, Ruston is stepping down from the CEO role, having guided the company from its inception to this critical inflection point. His decision reflects a strategic understanding of the different leadership skills required for different stages of a biotech's life cycle.

In his own words, Ruston acknowledged the significance of the moment. “It has been a great privilege to have led Persica in the development of PP353,” he said. “Having reached this pivotal point, I have decided the time has come to hand over the reins to someone who can see our product to market and make our dream of improving the lives of many cLBP patients a reality.”

Ruston’s continued involvement as a Non-Executive Director ensures that his foundational knowledge and long-term vision will not be lost. This model of a founder handing off operational control to seasoned late-stage experts while remaining as a strategic advisor is a hallmark of mature and well-planned corporate governance in the biotech sector. It provides stability and continuity while injecting the new, specialized expertise needed to navigate the complex road ahead. Dr. Littler acknowledged Ruston's foundational work, thanking him on behalf of the company "for his huge contribution over many years.”

Navigating the Path to Market

With a strengthened leadership team and compelling clinical data, Persica Pharmaceuticals is now squarely focused on the future. The primary challenge will be to successfully shepherd PP353 through larger, more expensive Phase 2 and Phase 3 clinical trials. These studies will be essential to confirm the safety and efficacy observed in the Phase 1b trial in a larger patient population and to satisfy the rigorous demands of regulatory agencies like the FDA and EMA.

This is precisely where the experience of Littler and Watson becomes invaluable. Watson’s track record in late-stage program leadership and fundraising will be crucial in designing and financing these trials, while Littler’s history of navigating companies towards successful regulatory and commercial outcomes provides the strategic oversight needed for the journey.

The potential prize is enormous. A safe, effective, disease-modifying, and non-opioid treatment for a major cause of chronic back pain would be a blockbuster product, addressing a vast unmet medical need and offering a vital alternative in the ongoing public health battle against opioid addiction. While the path through late-stage clinical development is never certain, Persica has now assembled the key ingredients—a promising asset, strong early data, and an experienced leadership team—to give it the best possible chance of success. The journey will be closely watched by patients, physicians, and investors alike.